Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: A randomised controlled study

Gianpiero Benetti, Mauro Borzio, Giuliano Ramella, Giorgio Bellati, Silvia Fargion, Alberto Colombo, Guido Croce, Carlo Iamoletti, Federico Balzola, Mario Rizzetto

Research output: Contribution to journalArticle


The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disappointing. In 1999, we started a multicentre study comparing two regimens of recombinant interferon (IFN) alpha-2b plus ribavirin. Group A (90 patients) received ribavirin plus IFN alpha-2b 5 MU/day for 1 month (induction therapy) followed by IFN alpha-2b 5 MU thrice weekly for 5 months. Group B (85 patients) received ribavirin plus IFN alpha-2b 5 MU thrice weekly for 6 months. Responders in both arms received IFN alpha-2b 3 MU thrice weekly for a further 6 months. A followup evaluation was performed at 18 months. One hundred and seventy-five consecutive treatment-naive patients with HCV genotype 1 infection were enrolled in the study. A sustained virological response (SVR) was obtained in 51 (29%) patients: 28 in group A (31%) and 23 in group B (27%). HCV-RNA clearance was greater at 3 months among patients who received induction therapy (57 vs 39%; p

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalInternal and Emergency Medicine
Issue number2
Publication statusPublished - Jul 2006



  • Chronic hepatitis C
  • Cirrhosis
  • Genotype 1
  • Induction therapy

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine
  • Medicine(all)

Cite this